Heat shock protein 90 is a potential therapeutic target in cholangiocarcinoma

Molecular Cancer Therapeutics

Volumn 14, Issue 9, 2015, Pages 1985-1993

  Shirota, Tomoki ^a,b   Ojima, Hidenori ^a   Hiraoka, Nobuyoshi ^a   Shimada, Kazuaki ^c   Rokutan, Hirofumi ^a   Arai, Yasuhito ^a   Kanai, Yae ^a   Miyagawa, Shinichi ^b   Shibata, Tatsuhiro ^a,d  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; LUMINESPIB; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; ISOXAZOLE DERIVATIVE; RESORCINOL DERIVATIVE;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CHOLANGIOCARCINOMA CELL LINE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CHOLANGIOCARCINOMA; DISEASE MODEL; DRUG SCREENING; FOLLOW UP; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOXAZOLES; MALE; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; RESORCINOLS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941699706     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0069     Document Type: Article

References (34)

1. Hezel AF, Zhu Ax. Systemic therapy for biliary tract cancers. Oncologist 2008;13:415-23.
2. Aljiffry M, Abdulelah A, Walsh M, Pelekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systemic review of the current literature. J Am Coll Surg 2009;208:134-47.
3. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21.
4. Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013;32:4861-70.
5. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
6. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90 combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113:202-16.
7. Sekimoto T, Oda T, Pozo FM, Murakumo Y, Masutani C, Hanaoka F, et al. The molecular chaperone Hsp90 regulates accumulation of DNA polymerase eta at replication stalling sites in UV-irradiated cells. Mol Cell 2010;37:79-89.
8. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, et al. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther 2013;12:509-19.
9. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, et al. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther 2013;12:890-900.
10. Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al. Strong anti-tumor effect of NVP-AUY922, a novel HSP90 inhibitor, on non-small lung cancer. Lung Cancer 2012;76:26-31.
11. Bao XH, Takaoka M, Hao HF, Fukazawa T, Yamatsuji T, Sakamura K, et al. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer. Oncol Rep 2013;29:45-50.
12. Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, et al. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res 2012;32:2551-62.
13. Okui T, Shimo T, Hassan NM, Fukazawa T, Kurio N, Takaoka M, et al. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma. Anticancer Res 2011;31:1197-204.
14. Pick E, Kluger Y, Giltane JM, Moeder C, Camp RL, Rimm DL, et al. HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67:2932-7.
15. Song CH, Park SY, Eom KY, Kim JH, Kim SW, Kim JS, et al. Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res 2010;12:R20.
16. Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, et al. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget 2014;5:2372-89.
17. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008;98:418-25.
18. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer 2011;105:131-8.
19. Hamilton SR, Aaltonen LA. World Health Organization classification of tumours: pathology and genetics: tumours of the digestive system. Lyon: IARC Press;2000.
20. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009.
21. Lim So, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, et al. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol 2005;11:2072-9.
22. Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, et al. Establishment of six new human biliary tract carcinoma, cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci 2010;101:882-8.
23. Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, et al. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer 2013;119:293-303.
24. Zhu AX, Hezel AF. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology 2011;53:695-704.
25. Milicevic Z, Bogojevic D, Mihailovic M, Petrovic M, Krivokapic Z. Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression. Int J Oncol 2007;32:1169-78.
26. Yamada T, Hashiguchi A, Fukushima S, Kakita Y, Umezawa A, Maruyama T, et al. Function of 90 kDa heat shock protein in cellular differentiation of human embryonal carcinoma cells. In Vitro Cell Dev Biol Anim 2000;36:139-46.
27. Kim YS, Alarcon SV, Lee S, Lee MJ, Glaccone G, Neckers L, et al. Update on HSP90 in clinical trial. Curr Top Med Chem 2009;9:1479-92.
28. Graham B, Curry J, Smyth T, Fazal L, Feltell R, Harada I, et al. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci 2012;103:522-7.
29. Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, et al. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer 2013;12:128.
30. Shapiro Gl, Kwak E, Dezube BJ, Yule M, Ayrton J, Lyons J, et al. First-in-human phase I dose escalation study of second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin Cancer Res 2015;21:87-97.
31. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
32. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with Hsp90 and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858-66.
33. Jiao Y, Ou W, Meng F, Zhou H, Wang A. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer 2011;10:125.
34. Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, et al. Antitumor activity of the HSP90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol Cancer Ther 2011;10:817-24.